396 results match your criteria Dementia: Overview of Pharmacotherapy


Role of "light therapy" among older adults with dementia: an overview and future perspectives.

Geriatr Psychol Neuropsychiatr Vieil 2019 Mar;17(1):83-91

Unité de psychologie de la sénescence, Université de Liège (ULiège), Belgique.

Given the relatively modest therapeutic benefits of drug treatments (and their associated costs) in dementia, there is a growing interest in non pharmacological approaches, including light therapy (light based therapy, LBT). Although various literature reviews exist, little attention has been given to the effects of these therapies (according to their modalities of application) on parameters related to both circadian rhythm and clinical parameters associated with dementia.

Aims: To provide an overview of available studies using LBT as non-pharmacological approach for managing persons with dementia and to make recommendations for its use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/pnv.2019.0786DOI Listing
March 2019
10 Reads

Alzheimer's disease therapeutic candidate SAK3 is an enhancer of T-type calcium channels.

J Pharmacol Sci 2019 Feb 18;139(2):51-58. Epub 2018 Dec 18.

Institute of Pharmacology and Toxicology and Biochemical Pharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.

Low-threshold Ca spikes are mediated by T-type Ca channels, which have electrophysiological properties of fast inactivation and slow deactivation kinetics. A low membrane potential of approximately -60 mV is sufficient to trigger channel opening. We recently introduced a novel T-type Ca channel enhancer that improves cognition and inhibits amyloid beta aggregation in an Alzheimer's disease (AD) mouse model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jphs.2018.11.014DOI Listing
February 2019
1 Read

Overview on the Effects of -Acetylcysteine in Neurodegenerative Diseases.

Molecules 2018 Dec 13;23(12). Epub 2018 Dec 13.

IRCCS Centro Neurolesi "Bonino-Pulejo", Via Provinciale Palermo, Contrada Casazza, 98124 Messina, Italy.

-acetylcysteine (NAC), which is an acetylated cysteine compound, has aroused scientific interest for decades due to its important medical applications. It also represents a nutritional supplement in the human diet. NAC is a glutathione precursor and shows antioxidant and anti-inflammatory activities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23123305DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320789PMC
December 2018

WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.

Drug Resist Updat 2018 09 30;40:17-24. Epub 2018 Oct 30.

Department of Neurosurgery, Brain Tumor Center Amsterdam, Amsterdam University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HZ, Amsterdam, Netherlands. Electronic address:

Glioblastoma is the most common and malignant form of brain cancer, for which the standard treatment is maximal surgical resection, radiotherapy and chemotherapy. Despite these interventions, mean overall survival remains less than 15 months, during which extensive tumor infiltration throughout the brain occurs. The resulting metastasized cells in the brain are characterized by chemotherapy resistance and extensive intratumoral heterogeneity. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13687646183004
Publisher Site
http://dx.doi.org/10.1016/j.drup.2018.10.001DOI Listing
September 2018
18 Reads

[Atrial fibrillation as Risk Factor for Development of Cognitive Function Impairment and Dementia. Potential of Anticoagulant Therapy in Their Prevention].

Kardiologiia 2018 09;58(9):76-88

Medical Academy of Continuing Education.

This article presents an overview of data of Russian and foreign literature on possible associations between cognitive impairment and atrial fibrillation (AF). It includes modern classification of cognitive impairment, mechanisms of the effect of AF on cognitive functions and development of dementia, recommendations for the prevention of cognitive impairment in patients with AF. Special attention is paid to the assessment of cognitive status, and safe anticoagulant therapy, which is a priority in the prevention of cognitive impairment in patients with AF. Read More

View Article

Download full-text PDF

Source
September 2018
14 Reads

Can Arginase Inhibitors Be the Answer to Therapeutic Challenges in Alzheimer's Disease?

Neurotherapeutics 2018 10;15(4):1032-1035

International Centre for Neurotherapeutics, Dublin City University, 9, Dublin, Ireland.

While the extensive hunt for therapeutics combating Alzheimer's disease (AD) has fallen short of delivering effective treatments, breakthroughs towards understanding the disease mechanisms and identifying areas for future research have nevertheless been enabled. The majority of clinical trials with β- and γ-secretase modulators have been suspended from additional studies or terminated due to toxicity issues and health concerns. The lack of progress in developing innovative AD therapies has also prompted a resurgence of interest in more traditional symptomatic treatments with cholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists, as well as in the research of immune response modulators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-0668-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277284PMC
October 2018
1 Read

Advances in the pharmacotherapeutic management of dementia with Lewy bodies.

Expert Opin Pharmacother 2018 10 13;19(15):1643-1653. Epub 2018 Sep 13.

a Department of Clinical and Experimental Medicine , Unit of Neurology, University of Pisa , Pisa , Italy.

Introduction: Dementia with Lewy bodies (DLB) is the second most common type of dementia in people over 65 years of age. Given the complex clinical phenotype, the management of DLB may be challenging, especially considering that there is limited evidence about specific interventions, and there are currently no Food and Drug Administration (FDA)/European Medicines Agency (EMA)-approved medications.

Areas Covered: This article provides an overview of the current pharmacotherapy in DLB and gives review to the most recent drug candidates in clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1519548DOI Listing
October 2018
3 Reads

Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases.

Adv Mater 2018 Nov 31;30(46):e1801362. Epub 2018 Jul 31.

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, and the Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria, 3010, Australia.

Therapies directed toward the central nervous system remain difficult to translate into improved clinical outcomes. This is largely due to the blood-brain barrier (BBB), arguably the most tightly regulated interface in the human body, which routinely excludes most therapeutics. Advances in the engineering of nanomaterials and their application in biomedicine (i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adma.201801362DOI Listing
November 2018
52 Reads
17.493 Impact Factor

Pharmacotherapeutic strategies for treating epilepsy in patients with Alzheimer's disease.

Authors:
Benjamin Cretin

Expert Opin Pharmacother 2018 Aug 14;19(11):1201-1209. Epub 2018 Jul 14.

a Unité de Neuropsychologie , Service de Neurologie des Hôpitaux Universitaires de Strasbourg , Strasbourg , France.

Introduction: Alzheimer's disease (AD)-related epileptic comorbidity is now well documented and appears to have been previously underestimated. Prescribing antiepileptic drugs (AEDs) in AD patients aims at preventing seizure-related morbi-mortality and the occurrence of deleterious status epilepticus. At the earlier stages of the disease, some clinicians even expect a disease-modifying effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2018.1496237DOI Listing
August 2018
37 Reads

Iron and Alzheimer's Disease: An Update on Emerging Mechanisms.

J Alzheimers Dis 2018 ;64(s1):S379-S395

Melbourne Dementia Research Centre, The Florey Institute of Neuroscience & Mental Health, The University of Melbourne, Parkville, VIC, Australia.

Iron is a crucial transition metal for life and is the most abundant transition metal in the brain. However, iron's biological utility as an effective redox cycling metal also endows it with the potential to catalyze production of noxious free radicals. This "Janus-faced" nature of iron demands a tight regulation of cellular its metabolism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/JAD-179944DOI Listing
January 2018
2 Reads

Assessing and Modulating Kynurenine Pathway Dynamics in Huntington's Disease: Focus on Kynurenine 3-Monooxygenase.

Methods Mol Biol 2018 ;1780:397-413

Department of Genetics and Genome Biology, University of Leicester, Leicester, UK.

The link between disturbances in kynurenine pathway (KP) metabolism and Huntington's disease (HD) pathogenesis has been explored for a number of years. Several novel genetic and pharmacological tools have recently been developed to modulate key regulatory steps in the KP such as the reaction catalyzed by the enzyme kynurenine 3-monooxygenase (KMO). This insight has offered new options for exploring the mechanistic link between this metabolic pathway and HD, and provided novel opportunities for the development of candidate drug-like compounds. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-7825-0_18DOI Listing
February 2019
3 Reads

Apelin, a promising target for Alzheimer disease prevention and treatment.

Neuropeptides 2018 Aug 23;70:76-86. Epub 2018 May 23.

Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Paramedical Faculty, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address:

Alzheimer's disease (AD) is a progressive neurodegenerative disease with high outbreak rates. It is estimated that about 35 million individuals around the world suffered from dementia in 2010. AD is expected to increase twofold every 20 years and, by 2030, approximately 65 million people could suffer from this illness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.npep.2018.05.008DOI Listing
August 2018
4 Reads

Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.

J Pharm Pharmacol 2018 Aug 16;70(8):985-993. Epub 2018 Apr 16.

Department of Biotechnology, National Institute of Technology Raipur, Raipur, India.

Objectives: Alzheimer's disease (AD) has become the primary cause of dementia. It shows a progressive cognitive dysfunction with degenerating neurons. Acetylcholine receptors (AChRs) propagate the cognitive ability and it consists of two primary members namely muscarinic (mAChRs) and nicotinic receptors (nAChRs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jphp.12919DOI Listing
August 2018
4 Reads
2.161 Impact Factor

An Overview on the Clinical Development of Tau-Based Therapeutics.

Authors:
Miguel Medina

Int J Mol Sci 2018 Apr 11;19(4). Epub 2018 Apr 11.

Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Queen Sofia Foundation Alzheimer Center, CIEN Foundation, Carlos III Institute of Health, 28031 Madrid, Spain.

Tauopathies such as Alzheimer's disease (AD), frontotemporal lobar degeneration, or progressive supranuclear palsy constitute a group of brain disorders defined by neurodegeneration and the presence of tau aggregates in the affected brains regions. Tau is a microtubule-associated protein that accumulates in the cytosol under pathological conditions, steering the formation of aggregates or inclusions thought to be involved in the degeneration and neuronal death associated with these diseases. Despite a substantial and unmet medical need for novel, more effective disease-modifying therapies for the treatment of AD and tauopathies, the last couple of decades have seen numerous drug development undertakings primarily focused on β-amyloid, with disappointing results to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/ijms19041160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5979300PMC
April 2018
1 Read

[Pharmacologic Therapies for Different Types of Dementia].

Brain Nerve 2018 Mar;70(3):211-220

Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori University.

We provide a general overview of pharmacologic treatments for different types of dementia in light of the Guidelines on the Clinical Management of Dementia in Japan 2017, clinical data not addressed in those guidelines, and the results of observational studies, focusing mainly on the treatment of Alzheimer-type dementia. In everyday clinical practice, patients must be provided with personalized treatment that strikes a balance between evidence-based treatment, as described in the guidelines and actual clinical circumstances. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.11477/mf.1416200983DOI Listing
March 2018
1 Read

Topical Discoveries on Multi-Target Approach to Manage Alzheimer's Disease.

Curr Drug Metab 2018 ;19(8):704-713

Quaid-e-Azam University, Islamabad, Pakistan.

Background: Alzheimer's disease (AD) is recognized as progressive multifaceted and multi-factorial neurodegenerative disorder which causes dementia among elderly people. Although, researchers in this field have put considerable efforts for the investigation of novel and appropriate therapeutic measures towards the cure of AD, unfortunately, no effective prevention therapy for this disease is available till date. In fact, various aspects involved in the onset and progression of AD are still disputed or uncovered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389200219666180305152553DOI Listing
November 2018
3 Reads

Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Drugs 2018 04;78(5):525-541

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, 7200 Cambridge, Suite 9A, Houston, TX, 77030, USA.

Tardive dyskinesia (TD) encompasses the spectrum of iatrogenic hyperkinetic movement disorders following exposure to dopamine receptor-blocking agents (DRBAs). Despite the advent of atypical or second- and third-generation antipsychotics with a presumably lower risk of complications, TD remains a persistent and challenging problem. Prevention is the first step in mitigating the risk of TD, but early recognition, gradual withdrawal of offending medications, and appropriate treatment are also critical. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0874-xDOI Listing
April 2018
19 Reads

Flavonoids in the Treatment of Alzheimer's and Other Neurodegenerative Diseases.

Curr Med Chem 2018 ;25(27):3228-3246

Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milan, Italy.

Flavonoids are phytochemicals present in almost all terrestrial plants and, as a consequence, in plant-based foods, and thus consumed by humans through diet. Recent evidences suggest that several flavonoids have positive effects against dementia and Alzheimer's disease, reversing age-related declines in neurocognitive performances. In this review, we provide a general classification of natural and synthetic flavonoids, a description of their physico-chemical properties, in particular their redox properties and stability, and an extensive overview about their biological activities and structure-activity relationship in the field of neurodegenerative diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867325666180209132125DOI Listing
September 2018
3 Reads

Re-education begins at home: an overview of the discovery of in vivo-active small molecule modulators of endogenous stem cells.

Expert Opin Drug Discov 2018 04 8;13(4):307-326. Epub 2018 Feb 8.

a New Drug Targets Laboratory, School of Life Sciences, Gwangju Institute of Science and Technology , Buk-Gu , Gwangju , Republic of Korea.

Introduction: Degenerative diseases, such as Alzheimer's disease, heart disease and arthritis cause great suffering and are major socioeconomic burdens. An attractive treatment approach is stem cell transplantation to regenerate damaged or destroyed tissues. However, this can be problematic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1437140DOI Listing
April 2018
65 Reads

Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows.

Expert Opin Ther Pat 2018 04 13;28(4):341-350. Epub 2018 Feb 13.

a State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences , University of Macau , Taipa , China.

Introduction: Today, over 20 million people suffer from Alzheimer's disease (AD) worldwide. AD has become a critical issue to human health, especially in aging societies, and therefore it is a research hotspot in the global scientific community. The technology flow method differs from traditional reviews generating an informative overview of the research and development (R&D) landscape in a specific technological area. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543776.2018.1439475DOI Listing
April 2018
5 Reads

Studies on the interaction of NMDA receptor antagonist memantine with cell membranes: A mini-review.

Chem Biol Interact 2018 Mar 31;283:47-50. Epub 2018 Jan 31.

Malopolska Centre of Biotechnology, Jagiellonian University, Kraków, Poland; Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.

Memantine is an NMDA receptor antagonist clinically used for the treatment of moderate to severe Alzheimer's disease. Currently, it is the only NMDA receptor antagonist drug marketed against this disease. Despite the large number of publications regarding its clinical and therapeutic use, studies related to its mechanism of action are still inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cbi.2018.01.022DOI Listing
March 2018
4 Reads

Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.

Molecules 2018 Jan 27;23(2). Epub 2018 Jan 27.

Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari "Aldo Moro", via E. Orabona 4, I-70125 Bari, Italy.

Many naturally occurring substances, traditionally used in popular medicines around the world, contain the coumarin moiety. Coumarin represents a privileged scaffold for medicinal chemists, because of its peculiar physicochemical features, and the versatile and easy synthetic transformation into a large variety of functionalized coumarins. As a consequence, a huge number of coumarin derivatives have been designed, synthesized, and tested to address many pharmacological targets in a selective way, e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/molecules23020250DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017103PMC
January 2018
2 Reads

An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer's disease.

Pharmacol Res 2018 04 26;130:420-437. Epub 2017 Dec 26.

Laboratory of Neuronal Cell Signaling, EBRI "Rita Levi-Montalcini" Foundation, Rome, Italy; Laboratory of Neurobiology in Translational Medicine, Department of Neurorehabilitation Sciences, Casa Cura Policlinico, Milan, Italy. Electronic address:

Nowadays, Alzheimer's disease (AD) is recognized as a multifactorial neurological pathology whose complexity is the cause of our still low achievements in the understanding of the associated mechanisms as well the discovery of a possible definitive cure. Clinicians are aware of the few possibilities offered by medicine to cure Alzheimer's patients, restore their memory and take them back to normal life. Unfortunately, the therapeutic tools available today are not able to contrast the pathology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.phrs.2017.12.023DOI Listing

[Antibodies as treatment option in older adults].

Authors:
M Gosch S Wicklein

Z Gerontol Geriatr 2018 Feb 20;51(2):152-156. Epub 2017 Dec 20.

Medizinische Klinik 2 - Schwerpunkt Geriatrie, Universitätsklinik für Geriatrie, Klinikum Nürnberg, Paracelsus Medizinische Privatuniversität, Campus Nürnberg, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland.

Monoclonal antibodies are already used for many different clinical indications. Besides oncology and rheumatology, denosumab is the only antibody that is currently prescribed in older adults with osteoporosis; however, apart from osteoporosis there might be more possible indications for the use of antibodies in chronic diseases and geriatric syndromes. Particularly, with respect to sarcopenia the transition to "doping for older adults" seems to be fluent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00391-017-1352-xDOI Listing
February 2018
2 Reads

Targeting Neuroinflammation to Treat Alzheimer's Disease.

CNS Drugs 2017 12;31(12):1057-1082

Experimental Neuroinflammation Laboratory, Department of Experimental Medical Sciences, Biomedical Centrum (BMC), Lund University, Lund, Sweden.

Over the past few decades, research on Alzheimer's disease (AD) has focused on pathomechanisms linked to two of the major pathological hallmarks of extracellular deposition of beta-amyloid peptides and intra-neuronal formation of neurofibrils. Recently, a third disease component, the neuroinflammatory reaction mediated by cerebral innate immune cells, has entered the spotlight, prompted by findings from genetic, pre-clinical, and clinical studies. Various proteins that arise during neurodegeneration, including beta-amyloid, tau, heat shock proteins, and chromogranin, among others, act as danger-associated molecular patterns, that-upon engagement of pattern recognition receptors-induce inflammatory signaling pathways and ultimately lead to the production and release of immune mediators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-017-0483-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747579PMC
December 2017
5 Reads

Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

eNeurologicalSci 2017 Sep 2;8:44-53. Epub 2017 Jul 2.

Hospital Santa Creu i Sant Pau, Ciberned, Universitat Autònoma de Barcelona, Universitat Oberta de Catalunya, Barcelona, Spain.

Advanced Parkinson's disease (APD) is characterized by increased functional disability, caused by motor complications, the presence of axial symptoms, and emergent disease- and drug-related non-motor symptoms. One of the advanced therapies available is intrajejunal infusion of levodopa/carbidopa intestinal gel (LCIG); however, patient selection for this treatment is sometimes difficult, particularly because of overlapping indications with other alternatives. In recent years, strong evidence has supported the use of LCIG in treating motor fluctuations associated with APD, and several clinical studies provide emerging evidence for additional benefits of LCIG treatment in certain patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ensci.2017.06.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730910PMC
September 2017
43 Reads

The wonderland of neuronal nicotinic acetylcholine receptors.

Biochem Pharmacol 2018 05 14;151:214-225. Epub 2017 Dec 14.

Department of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, Augusta 30912, Georgia.

Nearly 30 years of experimental evidence supports the argument that ligands of nicotinic acetylcholine receptors (nAChRs) have potential as therapeutic agents. However, as in the famous Lewis Carroll novel "Alice in Wonderland", there have been many unexpected adventures along the pathway of development, and few nAChR ligands have been approved for any clinical condition to date with the exception of nicotine dependence. The recent failures of nAChR ligands in AD and schizophrenia clinical trials have reduced enthusiasm for this therapeutic strategy and many pharmaceutical companies have now abandoned this field of research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bcp.2017.12.008DOI Listing
May 2018
7 Reads

An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia.

Int Psychogeriatr 2018 03 16;30(3):295-309. Epub 2017 Nov 16.

Department of Rehabilitation,Aged and Extended Care,Faculty of Medicine,Nursing and Health Sciences,School of Health Sciences,Flinders University,Level 1,C Block,Repatriation General Hospital,Daw Park,SA,Australia.

ABSTRACTBackground:This systematic overview reports findings from systematic reviews of randomized controlled trials of pharmacological and non-pharmacological interventions for behavioural and psychological symptoms of dementia (BPSD).

Methods: The Cochrane Database of Systematic Reviews, DARE, Medline, EMBASE, and PsycINFO were searched to September 2015.

Results: Fifteen systematic reviews of eighteen different interventions were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/S1041610217002344DOI Listing
March 2018
16 Reads

RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes.

Authors:
V A Gault

Diabet Med 2018 01 1;35(1):33-40. Epub 2017 Nov 1.

School of Biomedical Sciences, University of Ulster, Coleraine, UK.

The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) have attracted considerable scientific and clinical interest due largely to their insulin-releasing and glucose-lowering properties. Indeed, GLP-1-based therapies are now key treatment options for many people with diabetes worldwide. In contrast, GIP-based agents have yet to reach the clinic based primarily on the impaired insulinotropic action of GIP observed in people with diabetes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dme.13522DOI Listing
January 2018

Very Late-Onset Schizophrenia-Like Psychosis: A Clinical Update.

J Psychosoc Nurs Ment Health Serv 2018 Jan 9;56(1):37-47. Epub 2017 Oct 9.

Psychosis symptoms (delusions and hallucinations) are multifactorial in origin and, in later life, occur in the context of schizophrenia, delirium, dementia, delusional and schizophrenia-like disorders, mood disorders, and alcohol or substance abuse. The current article provides a clinical overview of very late-onset (after age 60) schizophrenia-like psychosis (VLOSLP), summarizing the literature on treatment options and reflecting on the role of psychiatric-mental health nurses (PMHNs). Increased awareness of the clinical presentation, key features, and evidence-based treatment options will assist PMHNs to confidently recognize this often under-diagnosed disorder and adopt a more assertive role in terms of engagement and follow up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3928/02793695-20170929-02DOI Listing
January 2018
27 Reads

The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review.

Eur J Pharmacol 2017 Nov 1;815:364-375. Epub 2017 Oct 1.

Department of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab 144411, India. Electronic address:

Alzheimer's disease (AD) is a generalized term used for the loss in memory and other intellectual abilities on levels serious enough to interfere with daily life. It accounts for 60-80% of dementia cases. The characteristic features include aggregation of Amyloid-Beta (Aβ) plaques and Tau Protein Tangles in the nervous tissue of brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejphar.2017.09.043DOI Listing
November 2017
18 Reads
2.532 Impact Factor

Phosphodiesterase-4B as a Therapeutic Target for Cognitive Impairment and Obesity-Related Metabolic Diseases.

Adv Neurobiol 2017 ;17:103-131

School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK.

People in modern, affluent societies are living longer but also becoming increasingly overweight. With increased life expectancy comes increased risk of developing age-related cognitive decline and neurodegenerative diseases, such that an increasing proportion of life may be lived with cognitive impairment as age increases. Obesity is associated with poorer cognitive function in elderly subjects, and often leads to ill-health arising from various complications such as metabolic syndrome and type-2 diabetes mellitus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-58811-7_5DOI Listing
January 2018
15 Reads

[Treatment of dementia].

Ned Tijdschr Geneeskd 2017 ;161:D1851

UMC Utrecht, Utrecht.

- Treatment options for patients with dementia are limited. This article provides an overview of possible interventions, both pharmaceutical and non-pharmaceutical, for Alzheimer's disease, vascular dementia and mixed dementia.- Pharmaceutical treatment options include cholinesterase inhibitors, memantine and experimental medication. Read More

View Article

Download full-text PDF

Source
June 2018
7 Reads

The Medicinal Chemistry of Natural and Semisynthetic Compounds against Parkinson's and Huntington's Diseases.

ACS Chem Neurosci 2017 11 15;8(11):2356-2368. Epub 2017 Sep 15.

Department of Pharmaceutical and Pharmacological Sciences, University of Padova , Padova 35131, Italy.

Among the diseases affecting the central nervous system (CNS), neurodegenerations attract the interest of both the clinician and the medicinal chemist. The increasing average age of population, the growing number of patients, and the lack of long-term effective remedies push ahead the quest for novel tools against this class of pathologies. We present a review on the state of the art of the molecules (or combination of molecules) of natural origin that are currently under study against two well-defined pathologies: Parkinson's disease (PD) and Huntington's disease (HD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.7b00283DOI Listing
November 2017

Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.

Eur J Med Chem 2017 Oct 29;139:153-167. Epub 2017 Jul 29.

Université Caen Normandie, France; UNICAEN, CERMN - EA 4258, FR CNRS 3038 INC3M, SF 4206 ICORE, bd Becquerel, F-14032 Caen, France. Electronic address:

Alzheimer's Disease (AD) is a neurodegenerative brain disorder in which many biological dysfunctions are involved. Among them, two main types of lesions were discovered and widely studied: the amyloid plaques and the neurofibrillary tangles (NFTs). These two lesions are caused by the dysfunction and the accumulation of two proteins which are, respectively, the beta-amyloid peptide and the tau protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2017.07.070DOI Listing
October 2017
25 Reads

Reasons for (not) discontinuing antipsychotics in dementia.

Psychogeriatrics 2018 Jan 26;18(1):13-20. Epub 2017 Jul 26.

Department Health Technology and Services Research, University of Twente, Enschede, The Netherlands.

Background: The gap between high antipsychotic prescription rates for patients with dementia and the guidelines' advice to prescribe cautiously indicates that barriers to discontinuation exist. This exploratory study used the theory of planned behaviour to give a first overview of the factors that influence physicians to discontinue antipsychotics in nursing home patients with dementia.

Methods: Forty-one physicians in the Netherlands completed an online survey based on the theory of planned behaviour. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/psyg.12280DOI Listing
January 2018
29 Reads

Classics in Chemical Neuroscience: Memantine.

ACS Chem Neurosci 2017 09 9;8(9):1823-1829. Epub 2017 Aug 9.

Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University School of Medicine , Nashville, Tennessee 37232, United States.

Memantine was the first breakthrough medication for the treatment of moderate to severe Alzheimer's disease (AD) patients and represents a fundamentally new mechanism of action (moderate-affinity, uncompetitive, voltage-dependent, N-methyl-d-aspartate (NMDA) receptor antagonist that exhibits fast on/off kinetics) to modulate glutamatergic dysfunction. Since its approval by the FDA in 2003, memantine, alone and in combination with donepezil, has improved patient outcomes in terms of cognition, behavioral disturbances, daily functioning, and delaying time to institutionalization. In this review, we will highlight the historical significance of memantine to AD (and other neuropsychiatric disorders) as well as provide an overview of the synthesis, pharmacology, and drug metabolism of this unique NMDA uncompetitive antagonist that clearly secures its place among the Classics in Chemical Neuroscience. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acschemneuro.7b00270DOI Listing
September 2017
20 Reads

Alzheimer's Disease: Dawn of a New Era?

J Pharm Pharm Sci 2017 ;20(0):184-225

School of Pharmacy, Chapman University, Irvine, CA, USA.

Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by a progressive decline in cognition and memory, leading to significant impairment in daily activities and ultimately death. It is the most common cause of dementia, the prevalence of which increases with age; however, age is not the only predisposing factor. The pathology of this cognitive impairing disease is still not completely understood, which has limited the development of valid therapeutic options. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18433/J3VS8PDOI Listing
December 2017
17 Reads

An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds.

Curr Med Chem 2017 Nov;24(34):3749-3773

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Background: Dementias and all related neurodegenerative diseases of the Central Nervous System (CNS) are a current issue arousing a great deal of interest in the international scientific community. This is due to the increasing number of patients suffering from these diseases. These pathologies represent a serious problem, not only concerning the quality of life of the patient, but in addition, the enormous economic efforts that society has to do for their treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867324666170712161829DOI Listing
November 2017
3 Reads

Multi-targeting Strategies for Alzheimer's Disease Therapeutics: Pros and Cons.

Curr Top Med Chem 2017 ;17(27):3017-3061

Department of Microbiology, University of Calcutta, 35 Ballygunge Circular Road, Kolkata - 700 019. India.

Alzheimer's Disease (AD) is a single major cause of dementia in middle to old age individuals involving several different etiopathological mechanisms that are yet to be properly characterized. Major invariant and characteristic features consist of the progressive cerebral deposition of the Amyloid β-protein (Aβ) and the neurofibrillary degeneration through Neurofibrillary Tangles (NFT) formed by hyperphosphorylation of the tau proteins in the regions of the brain that deal with memory and cognition. There are at least five subgroups of AD that can be identified by determining Cerebrospinal Fluid (CSF) levels of Aβ1-42, tau and ubiquitin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1568026617666170707130652DOI Listing
November 2017
4 Reads

Interplay between Autophagy, Exosomes and HIV-1 Associated Neurological Disorders: New Insights for Diagnosis and Therapeutic Applications.

Viruses 2017 07 6;9(7). Epub 2017 Jul 6.

Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL 33199, USA.

The autophagy-lysosomal pathway mediates a degradative process critical in the maintenance of cellular homeostasis as well as the preservation of proper organelle function by selective removal of damaged proteins and organelles. In some situations, cells remove unwanted or damaged proteins and RNAs through the release to the extracellular environment of exosomes. Since exosomes can be transferred from one cell to another, secretion of unwanted material to the extracellular environment in exosomes may have an impact, which can be beneficial or detrimental, in neighboring cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/v9070176DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5537668PMC
July 2017
46 Reads

The Complexity of Clinical Huntington's Disease: Developments in Molecular Genetics, Neuropathology and Neuroimaging Biomarkers.

Adv Neurobiol 2017 ;15:129-161

Centre for Brain Research, The University of Auckland, Private Bag 92019, Auckland, 1142, New Zealand.

Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder characterised by extensive neuronal loss in the striatum and cerebral cortex, and a triad of clinical symptoms affecting motor, cognitive/behavioural and mood functioning. The mutation causing HD is an expansion of a CAG tract in exon 1 of the HTT gene. This chapter provides a multifaceted overview of the clinical complexity of HD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-57193-5_5DOI Listing
November 2018
2 Reads

The Blood Brain Barrier and its Role in Alzheimer's Therapy: An Overview.

Curr Drug Targets 2018 ;19(2):155-169

RVS Technology Ammal College of Pharmacy, Coimbatore, Tamil Nadu - 643001. India.

Background: Alzheimer's disease (AD) is the most frequent age related neurodegenerative disorder. It represents 70% of all dementia. Millions of people have been affected by AD worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389450118666170612100750DOI Listing
January 2018
29 Reads

Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.

Curr Drug Metab 2017 ;18(9):842-852

Department of Pharmacology and Toxicology, University of Hail, Hail. Saudi Arabia.

Background: Drug repurposing is an innovative approach as it provides new indications for already approved and established drugs. Due to high failure rates and cost involved in traditional drug development procedures, many pharmaceutical companies are primarily focusing on drug repurposing strategy. In Alzheimer disease (AD), existing therapeutic agents only provide symptomatic benefits and does not play a role in disease modification, therefore, an alternative strategy of repurposing can be used to inhibit neurodegeneracy process and other pathological complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389200218666170607101622DOI Listing
September 2018
8 Reads

Part 3: Impact of systemic conditions and medications on oral health.

Authors:
Diana Critchlow

Br J Community Nurs 2017 Apr;22(4):181-190

Senior Dental Officer, Northeast London NHS Foundation Trust, Dental Department, Grays Health Centre.

The people who are treated in the community setting will often have multiple comorbidities. Systemic medical conditions can have a negative impact on oral health. In addition, the medications used to treat systemic conditions may also themselves cause oral symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/bjcn.2017.22.4.181DOI Listing

WITHDRAWN: Interventions for fatigue and weight loss in adults with advanced progressive illness.

Cochrane Database Syst Rev 2017 04 7;4:CD008427. Epub 2017 Apr 7.

Faculty of Life and Health Sciences, University of Ulster, Shore Road, Newtownabbey, Co. Antrim Northern Ireland, UK, BT37 0QB.

Background: Fatigue and unintentional weight loss are two of the commonest symptoms experienced by people with advanced progressive illness. Appropriate interventions may bring considerable improvements in function and quality of life to seriously ill people and their families, reducing physical, psychological and spiritual distress.

Objectives: To conduct an overview of the evidence available on the efficacy of interventions used in the management of fatigue and/or unintentional weight loss in adults with advanced progressive illness by reviewing the evidence contained within Cochrane reviews. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD008427.pub3DOI Listing
April 2017
12 Reads

Pharmacological Management of Psychiatric Symptoms in Frontotemporal Dementia: A Systematic Review.

J Geriatr Psychiatry Neurol 2017 May 28;30(3):162-169. Epub 2017 Mar 28.

1 Department of Psychiatry, University of Milan, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.

Psychiatric symptoms in patients with frontotemporal dementia (FTD) are highly prevalent and may complicate clinical management of these patients. Purpose of the present article is to present and discuss available data about the pharmacological treatment of psychiatric symptoms in patients with FTD. A research in the main database sources has been conducted to obtain an overview of the pharmacological management of psychiatric symptoms in patients with FTD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0891988717700506DOI Listing
May 2017
7 Reads

Defining the Relationship Between Hypertension, Cognitive Decline, and Dementia: a Review.

Curr Hypertens Rep 2017 Mar;19(3):24

Department of Neurology, Johns Hopkins University School of Medicine, Phipps 446D 600 North Wolfe St., Baltimore, MD, 21287, USA.

Hypertension is a highly prevalent condition which has been established as a risk factor for cardiovascular and cerebrovascular disease. Although the understanding of the relationship between cardiocirculatory dysfunction and brain health has improved significantly over the last several decades, it is still unclear whether hypertension constitutes a potentially treatable risk factor for cognitive decline and dementia. While it is clear that hypertension can affect brain structure and function, recent findings suggest that the associations between blood pressure and brain health are complex and, in many cases, dependent on factors such as age, hypertension chronicity, and antihypertensive medication use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11906-017-0724-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164165PMC
March 2017
7 Reads

Mitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!

Handb Exp Pharmacol 2017 ;240:281-308

CNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 3004-517, Portugal.

Alzheimer's disease (AD) is a difficult puzzle to solve, in part because the etiology of this devastating neurodegenerative disorder remains murky. However, diabetes has been pinpointed as a major risk factor for the sporadic forms of AD. Several overlapping neurodegenerative mechanisms have been identified between AD and diabetes, including mitochondrial malfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/164_2017_3DOI Listing
December 2017
1 Read
2 Citations

Therapeutic potentials of herbal drugs for Alzheimer’s disease—An overview.

Indian J Exp Biol 2017 Feb;55(2):63-73

Alzheimer’s disease (AD) is a well known progressive neurodegenerative disorder having complex pathophysiology. Currently, drugs that are used symptomatically in the treatment of AD include acetylcholinesterase inhibitors (AChEIs) (rivastigmine, galantamine, donepezil) and N-methyl D-aspartate (NMDA) receptor antagonist (memantine). Limited bioavailability of these drugs stresses continuity of search for novel therapeutics for this slow growing but complex disease. Read More

View Article

Download full-text PDF

Source
February 2017